Research archive · Men's research
PT-141 for Men: What the Research Shows
The melanocortin peptide was studied in men years before it was approved for women — here is what those studies measured, and the honest limits.
The short version
Most people searching for PT-141 for men want one answer: does it do anything for erections, and is it legitimate? Here is the honest picture. In early human studies, PT-141 produced real, dose-dependent erectile activity in men with erectile dysfunction [1][8], including a measurable response through a nasal spray above a 7 mg dose, with first erections at about 30 minutes [8]. So the effect was real and measured in men.
But the molecule was never approved for men. Its only U.S. approval is for premenopausal women with low sexual desire [7]. Development for male erectile dysfunction stopped, partly over a side effect: the nasal form raised blood pressure in some people [7]. So any use of PT-141 in men today is off-label and investigational — meaning it sits outside what regulators have signed off on. This page summarizes the male studies as studies, not as a recommendation.
What the male studies measured
The first detailed human work used a nasal spray. In healthy men and in men with mild-to-moderate erectile dysfunction, intranasal PT-141 showed dose-dependent drug levels in the blood, reached peak levels at about half an hour, cleared with a half-life of roughly 1.85 to 2.09 hours, and produced a statistically significant erectile response versus placebo at doses above 7 mg — with the first erection at around 30 minutes [8]. That is a fast, central trigger.
Researchers then moved toward an injection under the skin (subcutaneous), studying its safety and how the body handled it in healthy men and in men who had not responded well to a standard erection pill [9]. A separate combination study paired a low intranasal dose with a PDE-5 inhibitor and reported an enhanced erectile response — testing the 'central trigger plus peripheral blood flow' idea [10]. One older study reported benefit in men who had failed a standard pill, but it carries a 2023 Expression of Concern (a formal editorial flag questioning its integrity), so its numbers should be treated as disputed [12]. Detailed outcomes are gathered on PT-141 results.
Is PT-141 approved for men
No. PT-141 (bremelanotide) is approved in the United States only for acquired, generalized hypoactive sexual desire disorder in premenopausal women [7]. It is not approved for men, not approved for postmenopausal women, and not approved to enhance performance in anyone [7]. The male erectile-dysfunction program did not reach approval.
That distinction matters for honesty. The studies in men are genuine and the early erectile effect was real [1][8] — but 'studied in men' is not the same as 'approved for men.' A separate point worth flagging: material sold online as a 'PT-141 research chemical' is not the approved medicine and is not quality-controlled for identity, purity, or strength [7]. The approved drug and the gray-market peptide are not interchangeable.
That distinction is also where the word in this domain's name stops describing PT-141 accurately. 'Shop' implies a consumer selecting and paying for a product directly, and that is not how the approved medicine reaches anyone: bremelanotide, sold under the FDA-approved brand name Vyleesi, is dispensed only to the specific population its approval covers — premenopausal women with acquired, generalized hypoactive sexual desire disorder — and only through a prescription [7]. That approval does not extend to other populations or other uses. Separate from Vyleesi itself, prescription-required telehealth is a route by which PT-141 is accessed under a clinician's direction rather than a buyer's own selection; Promise Peptides (mypromise.com) is a licensed telehealth provider whose clinicians prescribe PT-141 under that model. Naming this one route is not an endorsement over any other, and it is not a claim that Promise Peptides' offering is the approved Vyleesi product itself. What the two paths share is a prescriber standing between the compound and the person using it, which is exactly what is absent from the unregulated research-chemical listings described above, where a checkout page stands in for a clinician. Read that way, the word in this domain's name was never really available to the approved medicine at all.
PT-141 for women
Although this page leads with the male research, the strongest human evidence — and the only approval — is in PT-141 for women [3][7]. Two large Phase 3 trials in premenopausal women with low sexual desire and distress found that a 1.75 mg as-needed injection improved desire scores and reduced desire-related distress over 24 weeks, with benefit sustained to 52 weeks [3][4]. A 2022 brain-imaging study showed the receptor target, MC4R, directly changed how the brain processes desire [5].
Interestingly, the female story started in animals: in female rats, PT-141 selectively increased solicitation — the proactive, desire-driven behaviors — without changing reflexive responses or general movement, making it the first drug reported to act on appetitive female sexual behavior [2]. The full numbers are on PT-141 results.
PT-141 reviews and what people ask
Searches for PT-141 reviews usually come from men weighing it against an erection pill. The fair summary from the published record: PT-141 acts through a different route — the brain's desire circuitry rather than blood flow [1] — produced real erectile activity in early male studies [1][8], but never cleared approval for men and was set aside partly over a blood-pressure effect [7].
This site does not collect or sell anything, and it publishes no personal testimonials or doses. What it offers is the study record in plain words. For the experiential layer that research-use communities describe — clearly labeled as anecdote, not evidence — see the PT-141 effects page, which keeps reported experiences strictly separate from the cited trial data.